U.S. Cybersecurity Pushes Faster Patch Deadlines Amid Rising AI-Driven Threats 
GameStop Eyes eBay Acquisition as Stock Prices Surge After Hours 
Spirit Airlines Shuts Down Flights, Issues Refunds After Financial Collapse 
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit 
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks 
Meta Plans $13B AI Data Center Financing in Texas Amid Surging Big Tech Investment 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
BHP Attracts AI-Focused Investors as Copper Demand Surges 
Regis Resources and Vault Minerals to Merge in $10.7B Gold Deal 
Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
United Airlines Flight Hits Light Pole During Newark Landing, FAA Investigates 
NASHUA, N.H., May 08, 2018 -- iCAD, Inc. (NASDAQ:ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced that it will release financial results for the first quarter ended March 31, 2018 after the close of the market, and host a conference call at 4:30pm Eastern Time, on Monday, May 14, 2018.
| Monday, May 14th @ 4:30pm Eastern Time | ||
| Domestic: | (800) 239-9838 | |
| International: | (323) 794-2551 | |
| Conference ID: | 8849802 | |
| Webcast: | http://public.viavid.com/index.php?id=129486 | |
| Replays, available through May 28th | ||
| Domestic: | (844) 512-2921 | |
| International: | (412) 317-6671 | |
| Replay PIN: | 8849802 | |
In addition, a replay of the call will remain on the Company’s website (www.icadmed.com) until the Company releases its second quarter 2018 financial results.
About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast and colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit or www.icadmed.com or www.xoftinc.com.
CONTACTS:
Media Inquiries:
ARPR, LLC
Erin Bocherer
(855) 300-8209 x120
[email protected]
or
Investor Relations:
LifeSci Advisors
Jeremy Feffer
(212) 915-2568
[email protected]
